POSTERS RELATED TO PACRITINIB FROM ASCO 2016

June 14, 2016

Here are some additional posters on Pacritinib which were presented at ASCO 2016:

PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF): OUTCOMES IN PATIENTS (PTS) WITH BASELINE (BL) THROMBOCYTOPENIA

OUTCOMES IN PATIENTS WITH MYELOFIBROSIS AND RBC-TRANSFUSION DEPENDENCE IN THE PHASE III PERSIST-1 STUDY OF PACRITINIB VS. BEST AVAILABLE THERAPY

PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF): 72 WEEK FOLLOW-UP OF THE PHASE III PERSIST-1 TRIAL

PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF): LONG TERM FOLLOW-UP OF PATIENT REPORTED OUTCOMES (PROS) IN THE PHASE III PERSIST-1 TRIAL